FASTQ to report · Solid tumours, haematology, plasma, hereditary syndromes
QCI Interpret for Oncology provides a comprehensive solution for interpreting oncology NGS data, from raw FASTQ files to the final clinical report. It combines AI-assisted literature search with expert-curated data assessed by clinical experts and physicians. QCI Interpret for Oncology supports the analysis of solid tumours, haematological malignancies, liquid biopsy and hereditary cancer syndromes. More than 5 million patient cases have already been evaluated with QCI Interpret worldwide.
QCI Interpret (QIAGEN Clinical Insight) is a clinical decision support tool used by diagnostic labs to interpret NGS data and produce reports. It consists of two integrated applications and also offers the option of sending rare or novel variants to QIAGEN experts for interpretation through the QCI Precision Insights service (formerly N-of-One). QCI Interpret reduces the burden of in-house bioinformatics, shortens turnaround time and simplifies variant interpretation. Its clinical validity is supported by a study conducted with Mayo Clinic and published in Cancer Genetics in 2025, which showed high concordance between QCI classifications and ClinGen/CGC/VICC guidelines.
The tool combines manual curation by clinical experts with AI-powered automated processing. QCI Interpret is independent of the panel and sequencing platform used and can be used, for example, with Twist, Illumina, Roche or Ion Torrent solutions. The QCI Knowledge Base draws on more than 40 public and QIAGEN databases, including HGMD. For each variant, it continuously assesses pathogenicity and clinical significance according to ACMG guidelines for germline variants and AMP/ASCO/CAP guidelines for somatic variants.
Six steps that QCI Interpret automates, from raw sequencing data to the clinical report for the oncologist.
In QCI Secondary Analysis, an optional part of the solution, you select a preconfigured workflow for your diagnostic panel. The system performs quality control, mapping, deduplication and variant calling, then sends the VCF file directly to QCI Interpret. It processes exome data at 35× coverage in about one minute.
In QCI Interpret, you select the appropriate workflow, upload the VCF file and add clinical details about the case, such as the patient's diagnosis and control data.
A preliminary classification according to AMP/ASCO/CAP guidelines is displayed for each variant. Variants can be filtered and ranked by clinical significance, with the supporting evidence shown alongside.
The system matches the genomic profile and diagnosis with available treatment options and clinical trials in the region. Curated evidence helps determine which findings are clinically relevant and reportable.
More than 800,000 expert-reviewed variant summaries are available. Rare or novel variants can be sent to QCI Precision Insights experts for specialised interpretation, with results often available the same day.
The clinical report is fully customisable, for example with regard to the therapeutic relevance of variants, prognostic markers or co-occurring findings. The report can then be signed off and exported to the laboratory information system or other formats.
Computes pathogenicity and clinical actionability according to ACMG for germline variants and according to AMP, ASCO and CAP for somatic variants. Somatic variants are assigned to four tiers of clinical significance (Tiers 1–4). Users also have an overview of the classification criteria applied.
More than 800,000 preformulated variant impact summaries reviewed by clinical oncologists. The summaries can be used directly in the final report, and their standardised wording supports consistent reporting across cases and laboratories.
Rare or novel variants can be sent to the QCI Precision Insights service (formerly N-of-One). The resulting classification is often available the same day, in a format ready for use in the report.
An optional cloud service that processes data from FASTQ to VCF. It includes trimming of adapters and low-quality ends, mapping, deduplication and variant calling. It processes exome data at an average coverage of 35× in about one minute.
It can be customised for targeted panels, comprehensive genomic profiling, WES and WGS. It is compatible with Twist, Illumina, Roche and Ion Torrent solutions.
Enables SNVs and CNVs to be analysed together in a single view. The protein-level view shows variant positions and their impact, and also displays co-occurring variants together with the available clinical evidence.
Cases sent for preliminary expert review can subsequently be submitted for full expert review without creating a new test. Every variant is assessed by an expert.
For repeat somatic reports, prior treatment decisions can be reapplied automatically based on the variant and diagnosis history. This helps keep reporting consistent.
Users can upload and dynamically create custom gene lists beyond the predefined panels. Up to five custom lists are available.
The new “Addend Report” function creates a copy of an already signed-out test without re-running the analysis. The addendum is labelled directly in the test, in the test list and in the final PDF.
Comprehensive genomic profiling of solid tumours. The final report includes treatment options, relevant clinical trials in the region, prognostic markers and TMB and MSI assessment.
Supports the analysis of AML, ALL, CLL and MDS as well as other myeloid and lymphoid malignancies, using current clinical evidence and co-occurring variant analysis.
Interpretation of plasma cfDNA, taking variant allele frequency into account. Supports monitoring of minimal residual disease and treatment response. Guardant Health also uses QCI Precision Insights to interpret its findings.
Supports panels covering, for example, BRCA, Lynch syndrome, hereditary breast and ovarian cancer and paediatric tumours. Germline variants are classified according to ACMG guidelines using HGMD data.
QCI is also used by national cancer programmes, such as Japan's National Cancer Center (C-CAT), thanks to its extensive expert-curated database and its ability to match patients with suitable treatment options and clinical trials.
Preconfigured workflows for TruSight Oncology 500 and other commercially available panels allow rapid implementation in routine practice.
We'll plan a demo tailored to your panels, process test data and walk you through how your turnaround time will change. Access to Precision Insights and Secondary Analysis according to your needs.